Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
Princy N Kumar, Jules Hernández-Sánchez, Sandra Nagel, Yuning Feng, Fang Cai, Joseph Rabin, Caryn G Morse, Nandita R Nadig, Obaid Ashraf, Deepa B Gotur, Grace A McComsey, Khalid Gafoor, Patrick Perin, Sarah C Thornton, William Stubbings, Celia J F Lin, Larry Tsai, Princy N Kumar, Jules Hernández-Sánchez, Sandra Nagel, Yuning Feng, Fang Cai, Joseph Rabin, Caryn G Morse, Nandita R Nadig, Obaid Ashraf, Deepa B Gotur, Grace A McComsey, Khalid Gafoor, Patrick Perin, Sarah C Thornton, William Stubbings, Celia J F Lin, Larry Tsai
Abstract
Background: Tocilizumab, an interleukin 6 receptor (IL-6R) antagonist monoclonal antibody, has shown efficacy in patients with coronavirus disease 2019 (COVID-19) pneumonia, but the optimal dose is unknown.
Methods: Patients hospitalized for moderate to severe COVID-19 pneumonia were randomized 1:1 to receive standard of care treatment and 1-2 doses of intravenous tocilizumab 4 mg/kg or 8 mg/kg (open-label). Primary pharmacokinetic and pharmacodynamic end points were serum concentrations of tocilizumab and soluble interleukin 6 receptor (sIL-6R), IL-6, ferritin, and C-reactive protein (CRP), from baseline to day 60. The secondary end point was safety. Key exploratory efficacy end points included clinical status, time to discharge, mortality rate, and incidence of mechanical ventilation.
Results: Of 100 patients randomized, 49 received tocilizumab 4 mg/kg and 48 received 8 mg/kg. In pharmacokinetic and sIL-6R assessments, dose-dependent differences were seen in patients who received 1 or 2 doses of 4 or 8 mg/kg. Serum concentrations of IL-6, ferritin, and CRP and safety outcomes were comparable between groups. Through day 60, serious adverse events were reported in 30.6% and 25.0% of patients in the 4- and 8-mg/kg groups, respectively. Eight patients (16.3%) in the 4-mg/kg group and 6 (12.5%) in the 8-mg/kg group died. Exploratory time-to-event outcomes favored 8 mg/kg within the first 2 weeks.
Conclusions: In patients with moderate to severe COVID-19 pneumonia who received tocilizumab 4 or 8 mg/kg, pharmacokinetic and sIL-6R assessments showed expected dose-dependent effects; pharmacodynamic assessments and safety were comparable, with no new safety signals. Further study is required before a lower dose of tocilizumab can be recommended in patients with COVID-19 pneumonia.
Clinical trials registration: NCT04363736.
Keywords: COVID-19; pharmacodynamics; pharmacokinetics; safety; tocilizumab.
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
References
- J Clin Pharmacol. 2010 Jul;50(7):754-66
- Lancet. 2008 Mar 22;371(9617):987-97
- Lancet. 2020 Mar 28;395(10229):1054-1062
- Oncologist. 2018 Aug;23(8):943-947
- Clin Pharmacol Ther. 2020 Sep;108(3):425-427
- Rev Panam Salud Publica. 2020 Jun 01;44:e72
- Intensive Care Med. 2020 May;46(5):846-848
- EClinicalMedicine. 2020 Jun 20;24:100418
- BMJ. 2021 Jan 27;372:n244
- BMJ. 2021 Jan 20;372:n84
- N Engl J Med. 2020 Dec 10;383(24):2333-2344
- Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
- JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
- JAMA Intern Med. 2021 Jan 1;181(1):32-40
- Arthritis Rheum. 2011 Mar;63(3):609-21
- JAMA. 2020 Apr 7;323(13):1239-1242
- J Clin Invest. 2020 May 1;130(5):2620-2629
- Lancet. 2021 May 01;397(10285):1637-1645
- JAMA Intern Med. 2021 Jan 1;181(1):24-31
- Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
- Ann Rheum Dis. 2008 Nov;67(11):1516-23
- J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
- Clin Pharmacol Ther. 2021 Mar;109(3):688-696
- Ann Rheum Dis. 2016 Jun;75(6):1081-91
- Lancet. 2020 Feb 15;395(10223):507-513
- N Engl J Med. 2021 Apr 22;384(16):1503-1516
- N Engl J Med. 2021 Jan 7;384(1):20-30
Source: PubMed